FDA approves Bayer's Gadavist (gadobutrol) injection as the first and only contrast agent for use in cardiac magnetic resonance imaging in adult patients with known or suspected coronary artery disease

Bayer

15 July 2019 - Coronary artery disease is an important public health issue-- a disease that affects 16.5 million Americans.

Bayer announced today the U.S. FDA has approved Gadavist (gadobutrol) injection for use in cardiac magnetic resonance (MR) imaging to assess myocardial perfusion (stress, rest) and late gadolinium enhancement in adult patients with known or suspected coronary artery disease (CAD). 

Gadavist is now the first and only contrast agent FDA approved for use in cardiac MR – an important diagnostic tool for patients with CAD.

Read Bayer press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Outcome , US , Diagnostic agent